World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
72285
World Ranking
3678
National Ranking
364

Howard A. Burris publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Howard A. Burris sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 954 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Howard A. Burris D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Howard A. Burris sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Howard A. Burris is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their research portfolio spans several key areas within medicine and biochemistry, genetics, and molecular biology, with a significant focus on oncology and related subfields.

Their work is heavily concentrated in oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and surgery. These areas reflect a multidisciplinary approach to cancer treatment and underlying biological mechanisms.

Main research topics studied by Howard A. Burris include:

  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research

Burris has published extensively in multiple notable scientific venues. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Clinical Cancer Research
  • British Journal of Cancer

Key recent papers authored or co-authored by Burris encompass a range of clinical and therapeutic studies, including:

  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, 2022, NEJM Evidence
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study, 2021, The Lancet Oncology
  • Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma, 2020, Journal of Clinical Oncology
  • First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors, 2021, EClinicalMedicine
  • A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1, 2022, Journal of Clinical Oncology

Throughout their career, Burris has frequently collaborated with a number of other researchers. Frequent co-authors include:

  • David R. Spigel
  • Suzanne F. Jones
  • Do-Youn Oh
  • Manish R. Patel
  • Mohamed Bouattour

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett

  • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

    Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

    Ian E. Krop;Muralidhar Beeram;Shanu Modi;Suzanne F. Jones

  • Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    Josep Tabernero;Federico Rojo;Emiliano Calvo;Howard Burris

  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

    M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard

  • Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

    John D. Hainsworth;Sharlene Litchy;Howard A. Burris;Daniel C. Scullin

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

    Denise A. Yardley;Shinzaburo Noguchi;Kathleen I. Pritchard;Howard A. Burris

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

Frequent Co-Authors

Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
John D. Hainsworth
John D. Hainsworth Sarah Cannon Research Institute
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
F. Anthony Greco
F. Anthony Greco Sarah Cannon Research Institute
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Patricia LoRusso
Patricia LoRusso Yale University
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Mario Campone
Mario Campone Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re planning to study Medicine in the USA, you may also want to explore alternative health-related career paths, many of which can be started online. For those still in high school or looking to prepare early, the best online schools for high school students offer affordable introductory programs in health information management. These courses can provide a solid foundation before committing to a longer degree.

Careers in healthcare administration and support are also in high demand. If you’re interested in working with medical records without attending a traditional campus, you can find the cheapest medical billing and coding online courses that offer flexible, accredited training.

For aspiring nurses, there are now many options for cheapest np school online as well as affordable online nursing courses to help you start or advance your nursing career. These programs are designed for those seeking flexible pathways into the healthcare field and can often be completed while working or managing other commitments.

Best Scientists Citing Howard A. Burris

Trending Scientists

Recently Published Articles